EN
|
SE
Contact us
About
About BioInvent
Immuno-oncology
Value creation
Board of directors
Management team
Scientific advisory board
Career
Pipeline
Clinical pipeline
BI-1206
Haematological cancers
TB-403/THR-317
Pre-clinical pipeline
TAMs
Tregs
Technology
F.I.R.S.T™
n-CoDeR
Intellectual property
Manufacturing
Partners
Investors
Share price
Financial reports
Presentations
Corporate governance
Subscribe
Media
Press releases
Events
Scientific publications
Image bank
About
About BioInvent
Immuno-oncology
Value creation
Board of directors
Management team
Scientific advisory board
Career
Pipeline
Clinical pipeline
BI-1206
Haematological cancers
TB-403/THR-317
Pre-clinical pipeline
TAMs
Tregs
Technology
F.I.R.S.T™
n-CoDeR
Intellectual property
Manufacturing
Partners
Investors
Share price
Financial reports
Presentations
Corporate governance
Subscribe
Media
Press releases
Events
Scientific publications
Image bank
About
About BioInvent
Immuno-oncology
Value creation
Board of directors
Management team
Scientific advisory board
Career
Pipeline
Clinical pipeline
BI-1206
Haematological cancers
TB-403/THR-317
Pre-clinical pipeline
TAMs
Tregs
Technology
F.I.R.S.T™
n-CoDeR
Intellectual property
Manufacturing
Partners
Investors
Share price
Financial reports
Presentations
Corporate governance
Subscribe
Media
Press releases
Events
Scientific publications
Image bank
Investors
Welcome to the Investor's section
Financial calendar
27 Feb 2020
Financial Statement 2019
29 Apr 2020
Annual General Meeting
